Phosphine-oxygen substituted quinoxaline quinazolinone compound as well as preparation method and application thereof
Synthesis of phosphine oxygen instead of quinazoline and quinazolineone compounds through electrochemical method has solved the high cost and risk problems of oxidant participation in the prior art, and achieved an efficient and gentle synthesis process, which is a synthetic chemistry and pharmaceutical chemistry Provides a variety of intermediates.
Patent Information
- Application Number
- CN202411213845.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-31
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art requires oxidants when synthesizing quinazolinone compounds, resulting in high cost, high risk and limited structural diversity. In particular, there is no effective method for synthesis of quinazolinone skeletons.
The electrochemical method is used to synthesize phosphine oxygen-substituted quinazolinone compounds, and the electrolytic reaction between N-arylquinazolinone and phosphine oxygen compounds is performed in the electrolytic cell, and the catalysis is used for manganese acetate and ligands to generate phosphine oxygen substitution. Quinazoline quinazolineone compounds, no oxidant required.
The efficient synthesis of phosphine-oxy-substituted quinazoline and quinazoline compounds has been achieved, with mild conditions, low energy consumption and low environmental pollution, providing structural diversity intermediates for applications in the fields of synthetic chemistry and medicinal chemistry.
Smart Images

Figure CN118996447A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic synthesis, and specifically relates to phosphine-oxygen substituted quinoxaline and quinazolinone compounds and preparation methods and applications thereof. Background Art
[0002] As an important class of nitrogen-containing heterocyclic skeletons, quinazolinones are widely present in natural products, drugs and other bioactive molecules. For example, polycyclic quinazolinone alkaloids Luotonin A, Tryptanthrin, Evodiamine, Rutaecarpine, and Circumdatin H have good anticancer, antithrombotic, anti-inflammatory and antiallergic activities. In addition, the quinazolinone skeleton has also received extensive attention in the design of pesticide molecules. Studies have shown that quinazolinone derivatives have good antiviral, antibacterial and antifungal activities in the prevention and control of plant diseases. The commercialized fungicides Fluquinconazole and Proquinazid are two representative examples. In view of the unique physiological and pharmacological activities of compounds containing quinazolinone skeletons, chemists have been committed to developing efficient synthetic methods to obtain quinazolinone derivatives with diverse structures.
[0003] Due to the advantages of high efficiency and good atom economy, free radical tandem reactions are a very valuable strategy for synthesizing complex molecules, especially for cyclic compounds that are often found in natural products. Although there have been some reports on the synthesis of quinazolinone compounds using free radical tandem cyclization reactions, these reactions mainly focus on the use of alkenyl-substituted N-cyanoamides and alkenyl-substituted quinazolinones. Most of these reactions require the participation of oxidants, which are prone to danger in industrial applications and increase costs. In addition, the synthesis of structures such as quinoxaline and quinazolinone has not yet been reported. Summary of the invention
[0004] In view of the deficiencies in the above-mentioned prior art, the present invention provides phosphine-oxygen-substituted quinoxaline-quinazolinone compounds and preparation methods and applications thereof. The present invention synthesizes phosphine-oxygen-substituted quinoxaline-quinazolinone compounds by electrochemical method for the first time without the participation of oxidant in the reaction, and synthesizes chloro- or trivalent phosphine-substituted quinoxaline-quinazolinone compounds by using phosphine-oxygen-substituted quinoxaline-quinazolinone compounds as intermediates, which has broad application prospects in the fields of synthetic chemistry and medicinal chemistry.
[0005] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0006] The phosphine-oxygen-substituted quinoxaline-quinazolinone compound has the chemical structural formula: Among them, R 1is selected from methyl, methoxy or halogen atoms, wherein the halogen atoms are selected from fluorine, chlorine and bromine; R 2 is selected from 4-methylphenyl, 3-methylphenyl, 2,4-dimethylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 4-trifluoromethylphenyl, biphenyl, 1-naphthyl, 2-methylthiophenyl, 4-fluorophenyl, 3-fluorophenyl, 4-chlorophenyl, cyclohexyl or benzyl.
[0007] The present invention also provides a method for preparing a phosphine-oxy substituted quinoxaline-quinazolinone compound, comprising the following steps:
[0008] The general reaction formula for the synthesis is:
[0009]
[0010] The isonitrile-substituted N-arylquinazolinone compound and the phosphine oxide compound are used as raw materials and added to an electrolytic cell. Then, manganese acetate, ligand, electrolyte and solvent are added to the electrolytic cell and mixed evenly. The electrolysis is carried out at room temperature in an air atmosphere with a constant current of 4-8 mA for 3-6 hours. The ligand and Mn 2+ Coordination is beneficial to Mn 2+ At the anodic oxidation stage, Mn 3+ , Mn 3+ The phosphine oxide compound is oxidized to generate free radicals, and the free radicals are added in series to the isonitrile-substituted N-arylquinazolinone compound to obtain a cationic intermediate, and the cationic intermediate is deprotonated to obtain a reaction solution; the reaction solution is diluted with ethyl acetate, and then neutralized to neutrality with a saturated sodium bicarbonate solution, and then extracted, concentrated under reduced pressure, and purified by column chromatography to obtain a phosphine oxide-substituted quinoxaline and quinazolinone compound.
[0011] Preferably, the isonitrile-substituted N-arylquinazolinone compound is selected from 3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 8-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 7,8-dimethyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-8-fluoroquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-methoxyquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-fluoroquinazolin-4(3H)-one, 3-( 2-isocyanatophenyl)-7-bromoquinazolin-4(3H)-one, 6-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-methoxyquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-fluoroquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-chloroquinazolin-4(3H)-one, 5-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one or 3-(2-isocyanatophenyl)benzo[g]quinazolin-4(3H)-one.
[0012] Preferably, the phosphine oxide compound is selected from diphenylphosphine oxide, di(4-methylphenyl)phosphine oxide, di(3-methylphenyl)phosphine oxide, di(2,4-dimethylphenyl)phosphine oxide, di(4-methoxyphenyl)phosphine oxide, di(3-methoxyphenyl)phosphine oxide, di(4-trifluoromethylphenyl)phosphine oxide, dibiphenylphosphine oxide, di(1-naphthyl)phosphine oxide, di(2-methylthiophenyl)phosphine oxide, di(4-fluorophenyl)phosphine oxide, di(3-fluorophenyl)phosphine oxide, di(4-chlorophenyl)phosphine oxide, dicyclohexylphosphine oxide or dibenzylphosphine oxide.
[0013] Preferably, the molar ratio of the N-arylquinazolinone compound, the phosphine oxide compound, manganese acetate, the ligand and the electrolyte is 1:1.2-1.5:0.1-0.2:0.12-0.24:1-1.5.
[0014] Preferably, the ligand is selected from 1,10-phenanthroline, 2,2-bipyridine, 6,6-dimethyl-2,2-bipyridine, 6,6-dimethoxy-2,2-bipyridine or 4,4-di-tert-butyl-2,2-bipyridine.
[0015] Preferably, the electrolyte is selected from tetrabutylammonium acetate, tetrabutylammonium bromide or tetrabutylammonium trifluoromethanesulfonate.
[0016] Preferably, the solvent is selected from a mixed solvent of tetrahydrofuran, acetonitrile or dimethyl sulfoxide and acetic acid, and the volume ratio of tetrahydrofuran, acetonitrile or dimethyl sulfoxide to acetic acid is 1:2.
[0017] Preferably, the anode of the electrolysis is selected from graphite felt, graphite rod or graphite sheet, and the cathode is selected from platinum electrode.
[0018] Preferably, the column chromatography condition is a 200-300 mesh silica gel column, and the eluent for column chromatography purification consists of petroleum ether and ethyl acetate in a volume ratio of 1:1-1.5.
[0019] The present invention also protects the use of phosphine-oxygen-substituted quinoxaline-quinazolinone compounds in the preparation of chloroquinoxaline-quinazolinone compounds or in the preparation of trivalent phosphine-substituted quinoxaline-quinazolinone compounds, the chloroquinoxaline-quinazolinone compounds are used as coupling reagents, the trivalent phosphine-substituted quinoxaline-quinazolinone compounds are used as phosphine-containing ligands, and the coupling reagents and phosphine-containing ligands participate in the synthesis of drugs.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] 1. The present invention uses electrochemistry as a means to catalyze the reaction of isonitrile-substituted N-arylquinazolinone compounds and phosphine oxide compounds, thereby achieving efficient synthesis of phosphine oxide-substituted quinoxaline and quinazolinone compounds. The reaction conditions are mild, no oxidant is required, manganese acetate is cheap, energy consumption is low, environmental pollution is small, and functional group compatibility is good.
[0022] 2. The product generated by the present invention can be further converted into a chloro-substituted quinoxaline-quinazolinone compound or used in the preparation of a trivalent phosphine-substituted quinoxaline-quinazolinone compound, and has broad application prospects in the fields of synthetic chemistry and medicinal chemistry. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 It is the hydrogen nuclear magnetic resonance spectrum of the trivalent phosphine-substituted quinoxaline and quinazolinone compound of the present invention.
[0024] Figure 2 It is the carbon nuclear magnetic resonance spectrum of the trivalent phosphine-substituted quinoxaline and quinazolinone compound of the present invention.
[0025] Figure 3 It is the nuclear magnetic resonance phosphine spectrum of the trivalent phosphine-substituted quinoxaline and quinazolinone compound of the present invention.
[0026] Figure 4 It is the hydrogen nuclear magnetic resonance spectrum of the chloroquinoxaline and quinazolinone compound of the present invention.
[0027] Figure 5 It is the carbon nuclear magnetic resonance spectrum of the chloroquinoxaline and quinazolinone compound of the present invention.
[0028] Figure 6 It is the nuclear magnetic resonance phosphine spectrum of the chloroquinoxaline and quinazolinone compound of the present invention. DETAILED DESCRIPTION
[0029] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] Electrochemical catalysis has the advantages of mild reaction conditions, diverse reaction modes, and easy scalability. In particular, the electrochemically catalyzed hydrogen release coupling reaction has shown great application potential. Compared with the traditional oxidative coupling reaction, the electrochemically catalyzed hydrogen release coupling reaction utilizes two processes, anodic oxidation and cathode reduction hydrogen release, and can achieve the coupling of two nucleophilic reagents without the need for an equivalent oxidant. Based on this, the present invention proposes for the first time a phosphine-oxygen-substituted quinoxaline-quinazolinone compound and a preparation method thereof. The reaction does not require an oxidant and has the advantages of mild reaction conditions, a wide substrate range, and a high yield.
[0031] Example 1
[0032] A method for preparing 6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3aa) comprises the following steps:
[0033] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol, 10 mol%), 1,10-phenanthroline (6.48 mg, 0.036 mmol, 12 mol%) and tetrabutylammonium acetate (90.3 mg, 0.3 mmol, 1.0 equiv) were added in sequence, and then 4 mL Tetrahydrofuran and 2 mL of acetic acid were added, and then a graphite felt (20 mm × 12 mm × 2 mm) anode and a platinum sheet (15 mm × 15 mm × 0.3 mm) cathode were installed, and electrolysis was performed at 8 mA constant current for 3 h in air atmosphere at room temperature to obtain a reaction solution; the reaction solution was diluted with ethyl acetate and neutralized to neutrality with a saturated sodium bicarbonate solution, and the neutralized reaction solution was extracted, concentrated under reduced pressure, and purified by column chromatography (eluent PE / EA = 1:1) to obtain 6-diphenylphosphinoyl-12H-quinoxaline [2,1-b] quinazolin-12-one (3aa), the chemical structure of which is:
[0034] Yellow solid (114 mg, 85%), mp 260.6-261.2°C. 1 H NMR (400MHz, CDCl3) δ9.63 (dd, J = 8.1, 3.3Hz, 1H), 8.40 (d, J = 7.6Hz, 1H), 8.13-7.91 (m, 5H), 7.82-7.61 (m, 3H), 7.61-7.44 (m, 8H). 13 C{ 1 H}NMR(101MHz, CDCl3)δ161.6(d,J=0.9Hz),159.1(d,J=128.0Hz),144.8(s),13 8.9(d,J=25.6Hz),135.6(d,J=20.5Hz),134.9(s),132.2(s),132.1(d,J=9.7Hz) ,131.94(s),131.86(d,J=2.8Hz),131.6(s),131.1(s),128.5(d,J=2.1Hz),128. 4(s),128.2(d,J=12.7Hz),127.6(d,J=22.5Hz),127.3(s),121.2(s),120.5(s). 31 P NMR(162MHz, CDCl3)δ25.9(s).HRMS(ESI,m / z):[M+H] +,calcd.for C 27 H 19 N3O2P + :448.1209,found:448.1208.
[0035] Example 2
[0036] A method for preparing 8-methyl-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ba) comprises the following steps:
[0037] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 8-methyl-3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 8-methyl-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ba), the chemical structure of which is:
[0038] Yellow solid (124 mg, 90%), mp 284.6-285.6°C. 1 H NMR (400MHz, CDCl3) δ9.64(d,J=8.7Hz,1H),8.24(d,J=8.0Hz,1H),7.91(dd,J=12.2,7. 6Hz, 4H), 7.81 (d, J = 7.8Hz, 1H), 7.65 (t, J = 8.0Hz, 1H), 7.60-7.39 (m, 9H), 2.17 (s, 3H). 31 P NMR(162MHz, CDCl3)δ27.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 28 H 21 N3O2P +:462.1366,found:462.1369.
[0039] Example 3
[0040] A method for preparing 8,9-dimethyl-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ca) comprises the following steps:
[0041] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 7,8-dimethyl-3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 8,9-dimethyl-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ca), the chemical structure of which is:
[0042] Yellow solid (124 mg, 90%), mp 284.6-285.6°C. 1 H NMR (400MHz, CDCl3) δ9.64(d,J=8.7Hz,1H),8.24(d,J=8.0Hz,1H),7.91(dd,J=12.2,7. 6Hz, 4H), 7.81 (d, J = 7.8Hz, 1H), 7.65 (t, J = 8.0Hz, 1H), 7.60-7.39 (m, 9H), 2.17 (s, 3H). 31 P NMR(162MHz, CDCl3)δ27.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 28 H 21 N3O2P + :462.1366,found:462.1369.
[0043] Example 4
[0044] A method for preparing 8-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3da) comprises the following steps:
[0045] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-8-fluoroquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv)), then add 4mL tetrahydrofuran and 2mL acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 8-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3da), the chemical structure of which is:
[0046] Yellow solid (106 mg, 76%), mp 253.6-254.3 °C. 1 H NMR (400MHz, CDCl3) δ9.59 (d, J = 8.6Hz, 1H), 8.27-8.05 (m, 6H), 7.77-7.66 (m, 1H), 7.65-7.42 (m, 9H). 31 P NMR (162 MHz, CDCl3) δ 24.8 (s). 19 F NMR(376MHz, CDCl3)δ-121.8(s).HRMS(ESI,m / z):[M+H] + ,calcd.forC 27 H 18 FN3O2P + :466.1115,found:466.1118.
[0047] Example 5
[0048] A method for preparing 9-methoxy-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ea) comprises the following steps:
[0049] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-7-methoxyquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 9-methoxy-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ea), the chemical structure of which is:
[0050] Yellow solid (72 mg, 51%), mp 246.6-247.1°C. 1 H NMR (400MHz, CDCl3) δ9.62(d,J=8.5Hz,1H),8.25(d,J=8.8Hz,1H),8.15-7.85(m,5H),7.81-7.39(m,10H),3.85(s,3H). 31 PNMR(162MHz,CDCl3)δ26.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 28 H 21 N3O3P + :478.1315,found:478.1316.
[0051] Example 6
[0052] A method for preparing 9-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3fa) comprises the following steps:
[0053] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-7-fluoroquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv)), then add 4mL tetrahydrofuran and 2mL acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1.5) to obtain 9-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3fa), the chemical structure of which is:
[0054] Yellow solid (82 mg, 59%), mp 245.7-246.5°C. 1 H NMR(400MHz, CDCl3) δ9.57(d,J=8.7Hz,1H),8.38(dd,J=8.9,5.9Hz,1H),8.05-7.88(m,5 H),7.71-7.61(m,1H),7.61-7.45(m,7H),7.28-7.21(m,1H),7.09(dd,J=9.1,2.4Hz,1H). 31 P NMR (162 MHz, CDCl3) δ 26.0 (s). 19 F NMR(376MHz, CDCl3)δ-101.3(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 18 FN3O2P + :466.1115,found:466.1117.
[0055] Example 7
[0056] A method for preparing 6-diphenylphosphinoyl-9-bromo-12H-quinoxaline [2,1-b] quinazolin-12-one (3ga) comprises the following steps:
[0057] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-7-bromoquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-diphenylphosphinoyl-9-bromo-12H-quinoxalino[2,1-b]quinazolin-12-one (3ga), the chemical structure of which is:
[0058] Yellow solid (88 mg, 56%), mp 260.2-260.8°C. 1 H NMR (400MHz, CDCl3) δ9.58(d,J=7.7Hz,1H),8.21(d,J=7.7Hz,1H),7.96(s,5H),7.58(dd,J=43.3,16.4Hz,10H). 31 P NMR(162MHz, CDCl3)δ26.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 18 BrN3O2P + :526.0315,found:426.0317.
[0059] Example 8
[0060] A method for preparing 10-methyl-6-diphenylphosphinoyl-12H-quinoxaline [2,1-b] quinazolin-12-one (3HA) comprises the following steps:
[0061] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 6-methyl-3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL tetrahydrofuran and 2mL acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 10-methyl-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ha), the chemical structure of which is:
[0062] Brown yellow solid (103 mg, 75%), mp 315.2-316.3°C. 1 H NMR (400MHz, CDCl3) δ9.59(d,J=8.6Hz,1H),8.14(s,1H),8.01(dd,J=12.2,7.2Hz,4H),7.93(d,J=7.8H z,1H),7.60(dd,J=11.6,4.4Hz,1H),7.50(dt,J=13.7,6.6Hz,8H),7.38(d,J=8.3Hz,1H),2.47(s,3H). 31 PNMR(162MHz,CDCl3)δ25.9(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 28 H 21 N3O2P + :462.1366,found:462.1365.
[0063] Example 9
[0064] A method for preparing 10-methoxy-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ia) comprises the following steps:
[0065] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-6-methoxyquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 10-methoxy-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ia), the chemical structure of which is:
[0066] Yellow solid (125 mg, 87%), mp 324.4-325.3 °C. 1 H NMR(400MHz, CDCl3)δ9.66(d,J=8.6Hz,1H),8.08-7.91(m,5H),7.73(d,J=2.1Hz,1H) ,7.64(t,J=7.8Hz,1H),7.59-7.40(m,8H),7.35(dd,J=8.9,2.3Hz,1H),3.93(s,3H). 31 P NMR(162MHz, CDCl3)δ26.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 28 H 21 N3O3P + :478.1315,found:478.1316.
[0067] Example 10
[0068] A method for preparing 10-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ja), comprising the following steps:
[0069] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)-6-fluoroquinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), diphenylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1.5) to obtain 10-fluoro-6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ja), the chemical structure of which is:
[0070] Yellow solid (74 mg, 53%), mp 250.0-250.8°C. 1 H NMR (400MHz, CDCl3) δ9.59 (d, J = 8.7Hz, 1H), 8.08-7.86 (m, 6H), 7.64 (t, J = 8.0Hz, 1H), 7.58-7.41 (m, 9H). 31 P NMR (162 MHz, CDCl3) δ 26.1 (s). 19 F NMR(376MHz, CDCl3)δ-109.1(s).HRMS(ESI,m / z):[M+H] + ,calcd.forC 27 H 18 FN3O2P + :466.1115,found:466.1114.
[0071] Embodiment 11
[0072] A method for preparing 6-bis(4-methylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ab) comprises the following steps:
[0073] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-methylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-methylphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ab), the chemical structure of which is:
[0074] Yellow solid (73.5 mg, 51%), mp 242.2-243.5°C. 1 H NMR (400MHz, CDCl3) δ9.60(d,J=8.3Hz,1H),8.38(d,J=7.3Hz,1H),7.98(d,J=7.4Hz,1H),7.88(dd,J=1 1.6, 8.1Hz, 4H), 7.76 (t, J = 7.3Hz, 1H), 7.68-7.60 (m, 1H), 7.59-7.51 (m, 3H), 7.28 (s, 4H), 2.38 (s, 6H). 31 PNMR(162MHz,CDCl3)δ26.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O2P + :476.1522,found:476.1524.
[0075] Example 12
[0076] A method for preparing 6-bis(4-methoxyphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ac) comprises the following steps:
[0077] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-methoxyphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-methoxyphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ac), the chemical structure of which is:
[0078] Yellow solid (87.5 mg, 57%), mp 289.4-290.5°C. 1 H NMR(400MHz, CDCl3)δ9.62(d,J=8.7Hz,1H),8.41(d,J=7.9Hz,1H),8.12-7.87(m,5H) ,7.78(t,J=7.6Hz,1H),7.72-7.51(m,4H),6.97(dd,J=8.7,2.1Hz,4H),3.83(s,6H). 31 P NMR(162MHz,CDCl3)δ25.5(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O4P + :508.1421,found:508.1423.
[0079] Embodiment 13
[0080] A method for preparing 6-bis(2,4-dimethylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ad) comprises the following steps:
[0081] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(2,4-dimethylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1.5) to obtain 6-bis(2,4-dimethylphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ad), the chemical structure of which is:
[0082] Yellow solid (78 mg, 52%), mp 267.2-268.1°C. 1 H NMR (400MHz, CDCl3) δ9.66(d,J=8.6Hz,1H),8.40(d,J=7.9Hz,1H),7.88(d,J=7.7Hz,1H),7.79-7.70(m,1H),7 .70-7.63(m,1H),7.51(ddd,J=21.7,13.2,7.6Hz,5H),7.07(dd,J=33.2,5.4Hz,4H),2.51(s,6H),2.36(s,6H). 31 P NMR(162MHz, CDCl3)δ34.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.forC 31 H 27 N3O2P + :504.1835,found:504.1835.
[0083] Embodiment 14
[0084] A method for preparing 6-bis(4-fluorophenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ae) comprises the following steps:
[0085] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-fluorophenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-fluorophenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ae), the chemical structure of which is:
[0086] Yellow solid (99 mg, 68%), mp 273.6-274.0°C. 1 H NMR(400MHz, CDCl3) δ9.57(d,J=8.5Hz,1H),8.34(d,J=7.8Hz,1H),8.12-7.88(m,6 H),7.79-7.70(m,1H),7.65-7.57(m,1H),7.56-7.44(m,3H),7.18(t,J=7.6Hz,3H). 31 P NMR (162 MHz, CDCl3) δ 24.4 (s). 19 F NMR(376MHz,DMSO)δ-108.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 17 F2N3O2P + :484.1201,found:484.1198.
[0087] Embodiment 15
[0088] A method for preparing 6-bis(4-chlorophenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3af) comprises the following steps:
[0089] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-chlorophenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-chlorophenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3af), the chemical structure of which is:
[0090] Yellow solid (79 mg, 51%), mp 273.6.-274.3°C. 1 H NMR (400MHz, CDCl3) δ9.61(d,J=8.6Hz,1H),8.39(d,J=7.9Hz,1H),7.91(dd,J=11.8,8.4H z,5H),7.79(t,J=7.4Hz,1H),7.66(t,J=7.7Hz,1H),7.53(ddd,J=21.5,13.5,7.1Hz,7H). 31 P NMR(162MHz, CDCl3)δ24.4(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 17 Cl2N3O2P + :516.0430,found:516.0433.
[0091] Example 16
[0092] A method for preparing 6-bis(4-trifluoromethylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ag), comprising the following steps:
[0093] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), bis(4-trifluoromethylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-trifluoromethylphenyl)phosphinooxy-12H-quinoxalino[2,1-b]quinazolin-12-one (3ag), the chemical structure of which is:
[0094] Yellow solid (98 mg, 56%), mp 272.0-272.9°C. 1 H NMR(400MHz, CDCl3) δ9.66(d,J=8.6Hz,1H),8.42(d,J=8.0Hz,1H),8.13(dd,J=11.7,8.2Hz,4H),7.97-7 .89(m,1H),7.79(t,J=7.8Hz,5H),7.74-7.68(m,1H),7.58(dt,J=9.8,7.6Hz,2H),7.45(d,J=8.1Hz,1H). 31 P NMR(162MHz, CDCl3)δ23.22(s). 19 F NMR(376MHz, CDCl3)δ-63.2(s).HRMS(ESI,m / z):[M+Na] + ,calcd.for C 29 H 16 F6N3NaO2P + :606.0777,found:606.0774.
[0095] Embodiment 17
[0096] A method for preparing 6-bis(4-phenylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ah) comprises the following steps:
[0097] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-phenylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(4-phenylphenyl)phosphinooxy-12H-quinoxalino[2,1-b]quinazolin-12-one (3ah), the chemical structure of which is:
[0098] Yellow solid (113 mg, 70%), mp 259.4-260.3 °C. 1 H NMR(400MHz, CDCl3) δ9.65(d,J=8.6Hz,1H),8.42(d,J=7.8Hz,1H),8.13(dd,J=11.5,8.3Hz,4H),8.03 (d,J=7.6Hz,1H),7.75(t,J=10.6Hz,5H),7.70-7.52(m,8H),7.45(t,J=7.3Hz,4H),7.41-7.35(m,2H). 31 PNMR(162MHz,CDCl3)δ25.5(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 39 H 27 N3O2P + :600.1832,found:600.1826.
[0099] Experimental Example 18
[0100] A method for preparing 6-bis(3-methylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ai) comprises the following steps:
[0101] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(3-methylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(3-methylphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ai), the chemical structure of which is:
[0102] Yellow solid (60 mg, 41%), mp 246.2-247.5°C. 1 H NMR (400MHz, CDCl3) δ9.64(d,J=8.7Hz,1H),8.41(d,J=8.0Hz,1H),8.00(d,J=7.8Hz,1H),7.88(d,J=1 2.7Hz,2H),7.76(d,J=7.3Hz,3H),7.67(t,J=7.9Hz,1H),7.62-7.50(m,3H),7.34(s,4H),2.39(s,6H). 31 PNMR(162MHz,CDCl3)δ26.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O2P + :476.1522,found:476.1524.
[0103] Experimental Example 19
[0104] A method for preparing 6-bis(3-methoxyphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3aj) comprises the following steps:
[0105] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(3-methoxyphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(3-methoxyphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3aj), the chemical structure of which is:
[0106] Yellow solid (105 mg, 70%), mp 240.7-241.3 °C. 1 H NMR (400MHz, CDCl3) δ9.63(d,J=8.7Hz,1H),8.40(d,J=8.0Hz,1H),7.98(d,J=7.8Hz,1H),7.77(t,J=7.6Hz,1H), 7.65(dd,J=16.1,8.3Hz,2H),7.60-7.48(m,6H),7.37(td,J=7.9,4.2Hz,2H),7.07(d,J=8.1Hz,2H),3.82(s,6H). 31 P NMR(162MHz, CDCl3)δ25.9(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O4P + :508.1421,found:508.1424.
[0107] Experimental Example 20
[0108] A method for preparing 6-bis(3-fluorophenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3ak) comprises the following steps:
[0109] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(3-fluorophenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1.5) to obtain 6-bis(3-fluorophenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ak), the chemical structure of which is:
[0110] Yellow solid (74 mg, 51%), mp 255.9-256.6°C. 1 H NMR (400MHz, CDCl3) δ9.63(d,J=8.7Hz,1H),8.41(d,J=7.9Hz,1H),7.94(d,J=7.7Hz,1H),7.85-7.64(m,6H),7.61-7.44(m,5H),7.26(t,J=7.4Hz,2H). 31 P NMR (162MHz, CDCl3) δ23.3 (t, J = 6.1Hz). HRMS (ESI, m / z): [M+H] + ,calcd.for C 27 H 17 F2N3O2P + :484.1201,found:484.1196.
[0111] Experimental Example 21
[0112] A method for preparing 6-bis(2-methylphenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3al) comprises the following steps:
[0113] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(2-methylphenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(2-methylphenyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3al), the chemical structure of which is:
[0114] Yellow solid (46 mg, 32%), mp 239.5-240.2°C. 1 H NMR (400MHz, CDCl3) δ9.60(d,J=8.6Hz,1H),8.36(d,J=7.8Hz,1H),7.98(d,J=7.5Hz,1H),7.88(d,J=12. 7Hz,2H),7.82-7.70(m,3H),7.67-7.60(m,2H),7.51(dd,J=13.1,6.0Hz,4H),7.34(s,4H),2.38(s,6H). 31 PNMR(162MHz,CDCl3)δ26.2(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O2P + :476.1522,found:476.1524.
[0115] Experimental Example 22
[0116] A method for preparing 6-bis(2-methylthiophenyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3am) comprises the following steps:
[0117] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(4-methylthiophenyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-bis(2-methylthiophenyl)phosphinooxy-12H-quinoxalino[2,1-b]quinazolin-12-one (3am), the chemical structure of which is:
[0118] Yellow solid (84 mg, 52%), mp 253.8-254.9°C. 1 H NMR (400MHz, CDCl3) δ9.66(d,J=8.2Hz,1H),8.39(d,J=7.2Hz,1H),7.90(ddd,J=10.8,9.0,4.4Hz,3H),7.66(ddd,J=13. 4,9.9,4.3Hz,2H),7.51(dd,J=12.8,7.2Hz,4H),7.44(dd,J=7.5,4.6Hz,2H),7.33(dd,J=13.4,7.3Hz,3H),2.26(s,6H). 31 P NMR(162MHz, CDCl3)δ29.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O2PS2 + :540.0964,found:540.0965.
[0119] Experimental Example 23
[0120] A method for preparing 6-di(1-naphthyl)phosphinoyl-12H-quinoxaline[2,1-b]quinazolin-12-one (3an) comprises the following steps:
[0121] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), di(1-naphthyl)phosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-di(1-naphthyl)phosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3an), the chemical structure of which is:
[0122] Yellow solid (113 mg, 69%), mp 353.1-354.2°C. 1 H NMR (400MHz, CDCl3) δ9.62(d,J=8.7Hz,1H),8.67(d,J=8.5Hz,2H),8.34(d,J=8.0Hz,1H),8.06(d,J=8.2Hz,2H),8.01(d,J=7.1Hz,1H),7.97(d,J=7.1H z,1H),7.92(d,J=8.1Hz,2H),7.64(q,J=8.0Hz,2H),7.56(d,J=7.8Hz,1H), 7.49(t,J=7.5Hz,5H),7.41(dd,J=15.8,7.7Hz,3H),7.28(d,J=8.2Hz,1H). 31 P NMR(162MHz,CDCl3)δ33.0(s).HRMS(ESI,m / z):[M+H] + ,calcd.forC 35 H 23 N3O2P + :548.1522,found:548.1529.
[0123] Experimental Example 24
[0124] A method for preparing 6-dicyclohexylphosphinoyl-12H-quinoxaline [2,1-b] quinazolin-12-one (3ao) comprises the following steps:
[0125] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), dicyclohexylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-dicyclohexylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ao), the chemical structure of which is:
[0126] Yellow solid (83 mg, 60%), mp 265.5-266.0°C. 1 H NMR (400MHz, CDCl3) δ9.61(d,J=8.5Hz,1H),8.49(d,J=7.8Hz,1H),8.21(d,J=7.5Hz,1H),7.91(q,J=8.0Hz,2H),7.81-7.54(m,3H),2.83-2.68(m ,2H),2.21(d,J=11.8Hz,4H),1.87(d,J=10.8Hz,2H),1.80-1.56(m,8H),1.43-1.27(m,2H),1.20(dd,J=22.7,10.8Hz,4H).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 31 N3O2P + :460.2148,found:460.2143.
[0127] Experimental Example 25
[0128] The preparation method of 6-dibenzylphosphinoyl-12H-quinoxaline [2,1-b] quinazolin-12-one (3ap) comprises the following steps:
[0129] In a dry 25 mL non-isolated electrolytic cell equipped with a magnetic stirrer, 3-(2-isocyanophenyl)quinazolin-4(3H)-one (0.3 mmol, 1.0 equiv), dibenzylphosphine oxide (0.36 mmol, 1.2 equiv), manganese acetate (5.19 mg, 0.03 mmol) were added in sequence. 10mol%), 1,10-phenanthroline (6.48mg, 0.036mmol, 12mol%) and tetrabutylammonium acetate (90.3mg, 0.3mmol, 1.0equiv), then add 4mL of tetrahydrofuran and 2mL of acetic acid, then install a graphite felt (20mm×12mm×2mm) anode and a platinum sheet (15mm×15mm×0.3mm) cathode, and electrolyze at 8mA constant current for 3h at room temperature in an air atmosphere to obtain a reaction solution; after diluting the reaction solution with ethyl acetate, neutralize it with a saturated sodium bicarbonate solution to neutrality, extract the neutralized reaction solution, concentrate it under reduced pressure, and purify it by column chromatography (eluent is PE / EA=1:1) to obtain 6-dibenzylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3ap), the chemical structure of which is:
[0130] Yellow solid (122 mg, 86%), mp 215.5-216.5°C. 1 H NMR (400MHz, CDCl3) δ9.58(d,J=8.7Hz,1H),8.52(d,J=8.0Hz,1H),8.16-7.93(m,3H),7.80-7.61(m,2H),7.55(t,J =7.5Hz,1H),7.30(dd,J=27.0,6.9Hz,5H),7.23-7.11(m,5H),3.89(dt,J=47.6,14.8Hz,4H).HRMS(ESI,m / z):[M+H] + ,calcd.for C 29 H 23 N3O2P + :476.1522,found:476.1519.
[0131] The phosphine-oxygen-substituted quinoxaline-quinazolinone compounds of the present invention are transformed and applied as follows:
[0132] Transformation Application 1. Preparation of trivalent phosphine-substituted quinoxaline and quinazolinone compounds:
[0133] The reduction of 6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3aa) comprises the following steps:
[0134] Under nitrogen atmosphere, 3aa (0.25 mmol), toluene (4 mL) and triethylamine (1.2 mmol) were added to a reaction tube (10 mL) equipped with a magnetic stirrer, then cooled to 0°C, and trichlorosilane (1.25 mmol) was added dropwise. After the addition, the mixture was reacted at 120°C for 18 h, and then cooled to room temperature to obtain a reaction solution. The reaction solution was concentrated under reduced pressure and purified by column chromatography (eluent: PE / EA = 1:5) to obtain 6-diphenylphosphino-12H-quinoxalino[2,1-b]quinazolin-12-one (4), the chemical structure of which is: 6-Diphenylphosphino-12H-quinoxalino[2,1-b]quinazolin-12-one can be used as a phosphine-containing ligand to participate in the synthesis of new compounds, and the new compounds can be used as drugs.
[0135] Yellow solid (21.5 mg, 20%), mp 214.8.0-215.6°C. 1 H NMR (400MHz, CDCl3) δ9.63(d,J=8.6Hz,1H),8.42(d,J=8.0Hz,1H),7.77(t,J=8.1Hz,2H) ,7.67(d,J=8.1Hz,1H),7.56(dd,J=15.7,7.5Hz,6H),7.49(t,J=7.5Hz,1H),7.36(s,6H). 13 C{ 1 H}NMR(101MHz, CDCl3)δ167.8(d,J=11.4Hz),162.2(s),145.4(s),140.2(d,J=24.1Hz),136.3(d,J=2.6Hz),135.4(d,J=6.6Hz),134.8(s),13 5.1-134.7(m),130.6(s),129.8(s),129.1(s),128.4(d,J=7.8Hz),12 8.0(d,J=3.0Hz),127.9(s),127.4(s),127.3(s),121.3(s),120.6(s). 31 PNMR(162MHz,CDCl3)δ-1.3(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 27 H 19 N3OP + :432.1260,found:432.1258,such as Figure 1-3 shown.
[0136] Transformation Application II: Preparation of Chloroquinoxaline and Quinazolinone Compounds:
[0137] The dephosphinochlorination reaction of 6-diphenylphosphinoyl-12H-quinoxalino[2,1-b]quinazolin-12-one (3aa) comprises the following steps:
[0138] 3aa (0.25 mmol) and dichloromethane (10 mL) were added to a dry round-bottom flask, and then oxalyl chloride (0.5 mmol) was added dropwise. After the addition, the mixture was stirred at room temperature for 0.5 h. The solvent was then dried and tetrahydrofuran (10 mL) was added. Finally, the mixture was cooled to 0°C, and LiAlH4 (0.275 mmol) was slowly added. After the addition, the mixture was stirred at room temperature for 3 h. After the reaction was completed, saturated ammonium chloride solution was slowly added at 0°C to quench the reaction to obtain a reaction solution. The reaction solution was extracted with ethyl acetate, concentrated under reduced pressure, and purified by column chromatography (eluent: PE / EA = 1:10) to obtain 6-chloro-12H-quinoxalo[2,1-b]quinazolin-12-one (5), the chemical structure of which is: 6-Chloro-12H-quinoxalino[2,1-b]quinazolin-12-one can be used as a coupling reagent, using a chlorine atom to participate in the coupling reaction.
[0139] Light yellow solid (62 mg, 88%), mp 214.8.0-215.6°C. 1 H NMR (400MHz, CDCl3) δ9.51(d,J=8.6Hz,1H),8.44(d,J=8.0Hz,1H),7.96(d,J=8.1Hz,1H) ,7.89(t,J=7.6Hz,1H),7.83(d,J=7.7Hz,1H),7.67-7.57(m,2H),7.54(t,J=7.5Hz,1H). 13 C{ 1 H}NMR(101MHz, CDCl3)δ161.7(s),150.7(s),145.1(s),137.3(s),135.2(s),133.8(s),130.2(s) ,129.3(s),128.9(s),128.5(s),127.8(s),127.5(s),121.1(s),120.6(s).HRMS(ESI,m / z):[M+H] + ,calcd.for C 15 H9ClN3O + :282.0429,found:282.0427,such as Figure 4-6 shown.
[0140] It should be noted that although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for preparing a phosphine-oxy substituted quinoxaline-quinazolinone compound. It is characterized in that The steps include: The isonitrile-substituted N-arylquinazolinone compound and the phosphine oxide compound are used as raw materials and added to an electrolytic cell. Then, manganese acetate, a ligand, an electrolyte and a solvent are added to the electrolytic cell. By using an electrochemical method, under the coordination of the ligand, Mn 2+ At the anodic oxidation stage, Mn 3+ , Mn 3+ Oxidizing a phosphine oxide compound to generate a free radical, and the free radical performs a series addition reaction on an isonitrile-substituted N-arylquinazolinone compound to obtain a cationic intermediate, and after the cationic intermediate is deprotonated, a phosphine oxide-substituted quinoxaline-quinazolinone compound is obtained; The general reaction formula for the synthesis is: Among them, R 1 is selected from methyl, methoxy or halogen atoms, wherein the halogen atoms are selected from fluorine, chlorine and bromine; R 2 is selected from 4-methylphenyl, 3-methylphenyl, 2,4-dimethylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 4-trifluoromethylphenyl, biphenyl, 1-naphthyl, 2-methylthiophenyl, 4-fluorophenyl, 3-fluorophenyl, 4-chlorophenyl, cyclohexyl or benzyl.
2. The method for preparing the phosphine-oxy substituted quinoxaline-quinazolinone compound according to claim 1, It is characterized in that The molar ratio of the N-arylquinazolinone compound, the phosphine oxide compound, manganese acetate, the ligand and the electrolyte is 1:1.2-1.5:0.1-0.2:0.12-0.24:1-1.
5.
3. The method for preparing the phosphine-oxy substituted quinoxaline-quinazolinone compound according to claim 1, It is characterized in that The isonitrile-substituted N-arylquinazolinone compound is selected from 3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 8-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 7,8-dimethyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-8-fluoroquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-methoxyquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-fluoroquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-methoxyquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-7-fluoroquinazolin-4(3H)-one, 3-(2- phenyl)-7-bromoquinazolin-4(3H)-one, 6-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-methoxyquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-fluoroquinazolin-4(3H)-one, 3-(2-isocyanatophenyl)-6-chloroquinazolin-4(3H)-one, 5-methyl-3-(2-isocyanatophenyl)quinazolin-4(3H)-one or 3-(2-isocyanatophenyl)benzo[g]quinazolin-4(3H)-one.
4. The method for preparing the phosphine-oxy substituted quinoxalinoquinazolinone compound according to claim 1, It is characterized in that The phosphine oxide compound is selected from diphenylphosphine oxide, di-(4-methylphenyl)phosphine oxide, di-(3-methylphenyl)phosphine oxide, di-(2,4-dimethylphenyl)phosphine oxide, di-(4-methoxyphenyl)phosphine oxide, di-(3-methoxyphenyl)phosphine oxide, di-(4-trifluoromethylphenyl)phosphine oxide, dibiphenylphosphine oxide, di-(1-naphthyl)phosphine oxide, di-(2-methylthiophenyl)phosphine oxide, di-(4-fluorophenyl)phosphine oxide, di-(3-fluorophenyl)phosphine oxide, di-(4-chlorophenyl)phosphine oxide, dicyclohexylphosphine oxide or dibenzylphosphine oxide.
5. The method for preparing the phosphine-oxy substituted quinoxalinoquinazolinone compound according to claim 1, It is characterized in that Electrolyze at a constant current of 4-8 mA for 3-6 hours.
6. The method for preparing the phosphine-oxy substituted quinoxalinoquinazolinone compound according to claim 1, It is characterized in that The ligand is selected from 1,10-phenanthroline, 2,2-bipyridine, 6,6-dimethyl-2,2-bipyridine, 6,6-dimethoxy-2,2-bipyridine or 4,4-di-tert-butyl-2,2-bipyridine.
7. The method for preparing the phosphine-oxy substituted quinoxalinoquinazolinone compound according to claim 1, It is characterized in that The electrolyte is selected from tetrabutylammonium acetate, tetrabutylammonium bromide or tetrabutylammonium trifluoromethanesulfonate.
8. The method for preparing the phosphine-oxy substituted quinoxalinoquinazolinone compound according to claim 1, It is characterized in that The solvent is selected from tetrahydrofuran, acetonitrile or a mixed solvent of dimethyl sulfoxide and acetic acid.
9. A phosphine-oxy substituted quinoxalinoquinazolinone compound obtained by the preparation method according to claim 1, It is characterized in that The structural formula of the phosphine-oxy substituted quinoxaline and quinazolinone compounds is: Among them, R 1 is selected from a methyl group, a methoxy group or a halogen atom; R 2 is selected from 4-methylphenyl, 3-methylphenyl, 2,4-dimethylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 4-trifluoromethylphenyl, biphenyl, 1-naphthyl, 2-methylthiophenyl, 4-fluorophenyl, 3-fluorophenyl, 4-chlorophenyl, cyclohexyl or benzyl.
10. Use of the phosphine-oxygen-substituted quinoxalinoquinazolinone compound according to claim 9 in the preparation of a chloroquinoxalinoquinazolinone compound or a trivalent phosphine-substituted quinoxalinoquinazolinone compound.
Citation Information
Patent Citations
Method for electrochemical synthesis of aryl-substituted quinoxaline (ketone) derivative
CN113774411A
Method for electrochemical synthesis of 7-thiocyano-3, 4-dihydroquinoxaline-2 (1H)-ketone compound
CN115928111A
Method for producing triarylphosphine derivative
JP2008196004A
6-substituted phosphoryl quinazoline derivative, preparation method therefor and use thereof
WO2022148442A1
